

PHASE II TRIAL OF RESPONSE-ADAPTED CHEMOTHERAPY BASED ON POSITRON EMISSION TOMOGRAPHY FOR NON-BULKY STAGE I AND II HODGKIN LYMPHOMA

Eligibility Criteria


Histologically documented stage IA, IB, IIA, IIB classical Hodgkin lymphoma.
 Nodular lymphocyte predominant Hodgkin lymphoma is excluded.
 No mediastinal mass > 0.33 maximum intrathoracic diameter or peripheral or retroperitoneal adenopathy > 10 cm (see Section 4.1.2)
 No prior treatment for Hodgkin lymphoma.
 Measurable disease (see Section 4.3).
 No currently active second malignancy other than non-melanoma skin cancers
 Performance Status 0-2
 LVEF by ECHO or MUGA within institutional normal limits.
 DLCO ≥ 60% with no symptomatic pulmonary disease.
 HIV+ patients are eligible, provided they meet the parameters in Section 4.8.
 Non-pregnant and non-nursing.
 Age 18 - 60 years.

Initial Required Laboratory Values

ANC	≥ 1000/ μ L
Platelet Count	≥ 100,000/ μ L
Serum Creatinine	≤ 2 mg/dL
Bilirubin	≤ 2 mg/dL
AST	≤ 2 x ULN

SCHEMA

Access to FDG-PET/CT imaging is a requirement for institutions enrolling patients on this protocol.



Note: Patients with progression will be removed from study treatment, but will be followed for OS.

* Follow-up according to the post-treatment schedule in Section 6.0.
 ** Biopsy may be performed if medically necessary at the discretion of the treating physician. If biopsy is neither clinically indicated nor medically appropriate, then patient should undergo a repeat PET/CT and CT scan three months later as noted in the footnote (‡) below.
 *** For HIV positive patients, standard BEACOPP will be used instead of escalated BEACOPP (see Section 7.1.3).
 ‡ If biopsy is neither clinically feasible nor appropriate, then repeat PET/CT and CT scans should be obtained 3 months later. If PET scan is negative, patient should be followed according to the post-treatment schedule in Section 6.0. If PET scan remains positive, at the discretion of the treating physician, patient may undergo biopsy if clinically feasible. If biopsy is negative, then patient should be followed according to the post-treatment schedule in Section 6.0. If biopsy is positive, patients should be followed as per Section 14.0. If biopsy is neither clinically appropriate nor medically feasible, patient should be followed according to the post-treatment follow-up schedule in Section 6.0.